Current Journal of Neurology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics and Malpractice Statement

AI policies

Indexing and Abstracting

Peer Review Process

Journal Metrics

Infections in patients with multiple sclerosis treated with disease-modifying therapies: A comparative risk assessment cohort study

Articles in Press

Document Type : Original Article

Authors

1 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

2 Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

3 Neurosurgery Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: The major treatment regimens for multiple sclerosis (MS) are disease-modifying therapies (DMTs). Fungal, viral, and bacterial infections are common complications of these drugs. Also, MS itself is an immune-related chronic disease that can compromise their subjects to infections. Therefore, MS can be a risk factor for infectious complications.
Methods: This paper is a retrospective cohort study conducted from February 2020 to January 2022 using prospectively collected data from every patient registered at the Multiple Sclerosis Referral Research Center in Tehran, Iran. We inducted patients with MS who were diagnosed based on McDonald's criteria and exposed to DMTs for at least 6 months prior to this study. Being under 18 years of age, diagnosis change during the study, and mortality were the exclusion criteria of this study.
Results: We inducted a total of 979 patients into this study. Finally, data from 798 participants were analyzed. Rituximab and natalizumab were associated with a higher risk of urinary tract infection (UTI) and bacterial vaginitis. 
Moreover, rituximab, glatiramer acetate, and dimethyl fumarate were associated with HSV-associated ulceration. None of the investigated DMTs were associated with an altered risk of COVID-19.
Conclusion: The use of DMTs can result in an increased risk of infections in patients. The selection of these DMTs should be based on their efficacy and risk of complications. Healthcare providers should familiarize themselves with these complications to select the appropriate DMTs with the highest efficacy.

Keywords

Main Subjects

References
  1. Sá MJ. Physiopathology of symptoms and signs in multiple sclerosis. Arq Neuropsiquiatr 2012; 70(9): 733-40.
  2. Woo MS, Engler JB, Friese MA. The neuropathobiology of multiple sclerosis. Nat Rev Neurosci 2024; 25(7): 493-513.
  3. Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol 2014; 14: 58.
  4. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4): 907-11.
  5. Briggs FB, Hill E. Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States. Mult Scler 2020; 26(14): 1948-52.
  6. Etemadifar M, Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Nasr Z. Estimated prevalence and incidence of multiple sclerosis in Iran. Eur Neurol 2014; 72(5-6): 370-4.
  7. Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol 2019; 76(5): 536-41.
  8. Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, et al. Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology 2021; 97(9): e869-e80.
  9. Mesgarof MA, Fattahi MR, Hemmati Z, Iranmehr A, Azizi H, Rahimi S. Genitourinary infectious complications in patients with multiple sclerosis and their association with disease modifying therapies. Transl Res Urol 2022; 4(2): 98-103.
  10. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007; 2007(4): Cd003982.
  11. Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12(4): 217-33.
  12. Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, et al. Disease-modifying drugs for multiple sclerosis and infection risk: A cohort study. J Neurol Neurosurg Psychiatry 2018; 89(10): 1050-6.
  13. Celius EG. Infections in patients with multiple sclerosis: Implications for disease-modifying therapy. Acta Neurol Scand 2017; 136 Suppl 201: 34-6.
  14. Gea-Banacloche JC. Rituximab-Associated Infections. Seminars in Hematology 2010; 47(2): 187-98.
  15. Alkadi A, Alduaiji N, Alrehaily A. Risk of tuberculosis reactivation with rituximab therapy. Int J Health Sci (Qassim) 2017; 11(2): 41-4.
  16. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol 2020; 77(2): 184-91.
  17. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994; 36 Suppl(Suppl): S25-8.
  18. Zhao J, Zeng W, Cao Y, Liang X, Huang B. Immunotherapy of HPV infection-caused genital warts using low dose cyclophosphamide. Expert Rev Clin Immunol 2014; 10(6): 791-9.
  19. Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis 2013; 4(4): 167-85.
  20. Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. Mult Scler 2020; 26(9): 1083-92.
  21. Rastas C, Sirignano D, Barner A, Bruno-Murtha LA. Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis. J Neurol 2019; 266(11): 2867-8.
  22. Maghbooli Z, Hosseinpour H, Fattahi MR, Varzandi T, Hamtaeigashi S, Mohammad-Nabi S, et al. Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection. Mult Scler Relat Disord 2022; 67: 104067.
  23. Cuschieri S. The STROBE guidelines. Saudi J Anaesth 2019; 13(Suppl 1): S31-s4.
  24. Shahin S, Eskandarieh S, Moghadasi AN, Razazian N, Baghbanian SM, Ashtari F, et al. Multiple sclerosis national registry system in Iran: Validity and reliability of a minimum data set. Mult Scler Relat Disord 2019; 33: 158-61.
  25. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-73.
  26. Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. CNS Drugs 2022; 36(12): 1285-99.
  27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
  28. Team RC. R language definition. Vienna, Austria: R foundation for statistical computing 2000; 3(1): 116.
  29. Stoica P, Selen Y. Model-order selection: A review of information criterion rules. IEEE Signal Process Mag 2004; 21(4): 36-47.
  30. Campetella M, Filomena GB, Marino F, Fantasia F, Russo P, Gavi F, et al. Etiology, presentation and management of urinary tract infections in multiple sclerosis patients: A review of the current literature. Urologia 2024; 91(2): 384-93.
  31. Langer-Gould AM, Smith JB, Gonzales EG, Piehl F, Li BH. Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm 2023; 10(6): e200164.
  32. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-401.
  33. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-15.
  34. Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, et al. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020; 78(1): 1-13.
  35. Højsgaard Chow H, Talbot J, Lundell H, Gøbel Madsen C, Marstrand L, Lange T, et al. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial. Neurol Neuroimmunol Neuroinflamm 2021; 8(5).
  36. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; 73(6): 705-13.
  37. Dempsey J, Balshi A, Sloane J. Herpes zoster infection in a patient with relapsing-remitting multiple sclerosis treated with diroximel fumarate. BMJ Case Rep 2025; 18(4): e264081.
  38. Thayer EL, Rizvi SA, Tung GA. Varicella Zoster Associated Vasculopathy and Retinitis with Natalizumab Use in Multiple Sclerosis. R I Med J (2013) 2024; 107(1): 26-8.
  39. Balshi A, Leuenberger G, Dempsey J, Manning N, Baber U, Sloane JA. Herpes Zoster Infections with Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study. Neurol Clin Pract 2025; 15(2): e200462.
  40. Balshi A, Saart E, Pandeya S, Dempsey J, Baber U, Sloane JA. High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate. Mult Scler 2023; 29(11-12): 1465-70.
  41. AlShammari RZ, AlOqayli FA, Alnafeesy SK, Al Thubaiti I. Reactivation of Herpes Zoster in a Young Patient with Multiple Sclerosis under Dimethyl Fumarate Treatment and Normal Lymphocyte Subsets Count: A Case Report. Cureus 2023; 15(12): e51412.
  42. Zabalza A, Thompson A, Rotstein DL, Bar-Or A, Montalban X. Multiple sclerosis and COVID-19: interactions and unresolved issues. Lancet Neurol 2025; 24(4): 361-70.
  43. Ghasemi M, Farazandeh D, Amini B, Sedaghat M, Najafi A, Khayatzadeh Kakhki S, et al. The association of upper respiratory infections with neuro-radiological course and attack rate of multiple sclerosis: Results from a large prospective cohort. Mult Scler J Exp Transl Clin 2023; 9(3): 20552173231196992.
  44. Etemadifar M, Nouri H, Pitzalis M, Idda ML, Salari M, Baratian M, et al. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A practical review and meta-analysis. J Neurol Neurosurg Psychiatry 2022; 93(9): 986-94.
  45. Mohammadpour M, Sahraian M, Moghadasi A, Navardi S. Mild COVID-19 infection in a patient with multiple sclerosis, while taking fingolimod: A case report. J Neurol Neurosci 2021; 44: 102314.
  46. Śladowska K, Kawalec P, Holko P, Osiecka O. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. Neurol Sci 2022; 43(9): 5479-500.
  47. Williamson EM, Berger JR. Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs 2015; 29(3): 229-44.
Current Journal of Neurology

Articles in Press, Accepted Manuscript
Available Online from 12 October 2025
Files
Share
How to cite
Statistics